Industrialization of cell therapy manufacturing: from artisanal process to scalable medicine

This perspective article focuses specifically on autologous and engineered cell therapies, including CAR‑T cell, tumor‑infiltrating lymphocyte (TIL), and stem cell therapies, where the patient’s own cells constitute the therapeutic product. While gene therapies using viral vectors (e.g., AAV, lentiviral) share some manufacturing challenges, they are addressed here only as far as they are integral to cell engineering workflows. The central argument is that industrialization – encompassing scalable manufacturing, advanced analytics, quality systems, and regulatory innovation – is no longer aspirational but operationally necessary to achieve widespread, affordable patient access.

Industrializing cell therapy manufacturing demands a transition from artisanal, patient-specific processes to scalable, automated, and digitally integrated systems — spanning modular scale-out, analytical QC, regulatory strategy, cost engineering, and global frugal innovation.

What you will learn

01

Why autologous cell therapy must scale out rather than scale up — and what currently limits this

02

How digital traceability, analytical QC, and AI enable quality assurance across the full manufacturing chain

03

How frugal innovation in India and the Middle East is redefining affordable, high-quality CGT production

The five pillars of CGT industrialization

1

Modular scale-out manufacturing

2

Digital chain of identity & analytical QC

3

CMC as a regulatory strategy

4

Sustainable COGS reduction

5

Frugal innovation & global manufacturing

Key findings

No approved autologous cell therapy has yet achieved profitability at scale — manufacturing economics, not the science, are the bottleneck

Transitioning to automated, closed-loop systems is the single most impactful lever for reducing cost of goods and eliminating operator-driven batch failure

India's tali-cel achieved a 98% manufacturing success rate across 60 centres at <$100,000 per patient — demonstrating that affordability is an industrial, not purely scientific, challenge

FDA's January 2026 CMC guidance enables phased compliance for Phase 1 CGT trials, allowing earlier first-in-human studies without full 21 CFR Part 211 requirements

Key interests

Cell & Gene Therapy

CAR-T Manufacturing

Process Automation

Analytical QC

Regulatory Strategy

Health Economics

Frugal Innovation